Status:
UNKNOWN
Optic Neuritis Differential Diagnosis Study
Lead Sponsor:
University Hospital Center of Martinique
Collaborating Sponsors:
University Hospital Center of Guadeloupe
Hospital Center of Cayenne (French Guyana)
Conditions:
Optic Neuritis
Neuromyelitis Optica
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background: Optic neuritis is a frequent cause of vision loss encountered by ophthalmologists in the Caribbean. The diagnosis is made on clinical grounds. Optic neuritis can occur either in an isolate...
Detailed Description
Background: Optic neuritis is a frequent cause of vision loss encountered by ophthalmologists in the Caribbean. The diagnosis is made on clinical grounds. Optic neuritis can occur either in an isolate...
Eligibility Criteria
Inclusion
- Patient aged 18 years or older at time of inclusion.
- Table of unilateral or bilateral optic neuritis defined as follows (clinical diagnosis):
- Visual sharpness (acuity and / or visual field) experienced acutely or subacutely (\<1 month) unilateral or bilateral, not corrected by optical correction.
- Absence of ophthalmologic lesion which may explain the visual loss.
- Examination of the normal fundus or showing a pallor or papular edema.
- Presence of relative pupillary deficit relative if unilateral attack.
- Patient (s) affiliated to a social security scheme (beneficiary or beneficiary).
- Patient who has given free and written consent.
Exclusion
- Patients known to have an inflammatory disease of the central nervous system (MS, NMO, EMAD).
- Known history of inflammatory pathology (lupus or sarcoidosis) or infectious pathology (syphilis, HIV) that may give rise to optical neuropathy.
- Table suggestive of Leber's hereditary optic neuropathy (genetically confirmed).
- Treatment in progress known to give optical neuropathies.
- Consumption of toxic known to give optical neuropathies.
- Drinking more than 3 alcohol drinks per day for men and 2 alcohol drinks per day for women over a period of more than 15 years.
- Arguments for non-arteritic ischemic optic neuropathy defined by all of the following criteria:
- Absence of pain in eye movements.
- Altitudinal deficit of the visual field.
- Choroidal ischemia with fluorescein angiography.
- Presence of cardiovascular risk factors.
- Absence of neurological signs related to inflammatory disease of the central nervous system.
- Arguments for arterial ischemic optic neuropathy defined by all of the following criteria:
- Absence of pain in eye movements.
- Altitudinal deficit of the visual field.
- Choroidal ischemia with fluorescein angiography.
- Presence of symptoms suggestive of Horton's disease.
- Absence of neurological signs related to inflammatory disease of the central nervous system.
- Pregnant and lactating patients.
Key Trial Info
Start Date :
June 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03370965
Start Date
June 7 2019
End Date
June 1 2025
Last Update
February 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU of Martinique
Fort-de-France, France, 97261